← Back to Clinical Trials
Recruiting NCT06364488

NCT06364488 TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06364488
Status Recruiting
Phase
Sponsor BlueSkeye AI
Condition Depression
Study Type INTERVENTIONAL
Enrollment 125 participants
Start Date 2024-10-01
Primary Completion 2026-07-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
TrueBlue App

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 125 participants in total. It began in 2024-10-01 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This trial will assess the safety, feasibility, acceptability, usability and agreement with validated scales of an automated mood monitoring App (TrueBlue), in adult, perinatal participants (recruited between 12 weeks of pregnancy and 12 weeks post-partum), recruited across multiple sites in Nottinghamshire, United Kingdom (UK). An initial within-study pilot phase will assess key aspects of the study including recruitment rate, usability issues and a detailed understanding of any device related adverse events; prior to full recruitment of a total 125 participants over a total 14-month period.

Eligibility Criteria

Inclusion Criteria: \- 18 years or older * Fluent in spoken and written English * Has capacity to provide consent * At least 12 weeks pregnant or less than 12 weeks postpartum * Access to internet connectivity * Access to a compatible smart phone device (for up to 10 participants, where needed through not having a personal device, this access may be provided through the study team). * Has a current GP within Nottinghamshire Exclusion Criteria: * ● Current clinically diagnosed psychiatric disorder other than depression * Previous history of a clinically diagnosed psychiatric disorder, other than depression and generalised anxiety disorder (including previous Psychosis, Bipolar Disorder, Personality Disorder, Substance Abuse Disorders, Eating Disorders) * Clinical diagnosis of an Autistic Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Parkinson's Disease or other current Neurological Disorder.

Contact & Investigator

Central Contact

John Michaelis, BSc

✉ john@blueskeye.com

📞 01689 856664

Principal Investigator

Neil Nixon, MBBS

PRINCIPAL INVESTIGATOR

School of Medicine, University of Nottingham and Nottinghamshire Healthcare NHS Trust

Frequently Asked Questions

Who can join the NCT06364488 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06364488 currently recruiting?

Yes, NCT06364488 is actively recruiting participants. Contact the research team at john@blueskeye.com for enrollment information.

Where is the NCT06364488 trial being conducted?

This trial is being conducted at Nottingham, United Kingdom, Nottingham, United Kingdom.

Who is sponsoring the NCT06364488 clinical trial?

NCT06364488 is sponsored by BlueSkeye AI. The principal investigator is Neil Nixon, MBBS at School of Medicine, University of Nottingham and Nottinghamshire Healthcare NHS Trust. The trial plans to enroll 125 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology